Sequencing of Agents in Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
-
Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.
-
Motzer RJ, Barrios CH, Kim TM, et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma. Paper presented at: 2013 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2013; Chicago, IL. Abstract 4504. J Clin Oncol 31, 2013 (suppl; abstr 4504).
-
Hutson T, Escudier B, Esteban E, et al. Temsirolimus vs Sorafenib as Second Line Therapy in Metastatic Renal Cell Carcinoma: Results From the INTORSECT Trial. Paper presented at: 37th European Society of Medical Oncology (ESMO) Congress; September 29-October 2, 2012; Vienna, Austria. Abstract 918.
-
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
-
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456.
Disclosure statements are available on the authors' profiles: